产品说明书

Piribedil

Print
Chemical Structure| 3605-01-4 同义名 : 吡贝地尔 ;Trivastal;Trivastan;EU 4200;ET 495
CAS号 : 3605-01-4
货号 : A254002
分子式 : C16H18N4O2
纯度 : 98%
分子量 : 298.34
MDL号 : MFCD00868264
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 35 mg/mL(117.32 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
靶点

  • α-adrenergic receptor

    adrenoceptor α2C, pKi:7.2

    adrenoceptor α2A, pKi:7.1
描述 Piribedil is a potent and orally active agonist for dopamine D2 and dopamine D3 receptors. Additionally, it acts as an antagonist for α2-adrenoceptors. Piribedil exhibits inhibition of MLL1 methyltransferase activity with an EC50 of 0.18 μM. Its potential applications include research related to Parkinson's disease, circulatory disorders, and cancers [1][2][3][4].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.35mL

0.67mL

0.34mL

16.76mL

3.35mL

1.68mL

33.52mL

6.70mL

3.35mL
参考文献

[1]Sweet RD, et al. Piribedil, a dopamine agonist, in Parkinson's disease. Clin Pharmacol Ther. 1974 Dec;16(6):1077-82.

[2]Gerlach M, et al. The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. J Neural Transm (Vienna). 2013 Jan;120(1):31-6.

[3]Smith LA, Tet al. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord. 2002 Sep;17(5):887-901.

[4]Xiong Zhang, et al. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis. Cancer Lett. 2018 Sep 1;431:150-160.